Water technology company Xylem (NYSE: XYL) fell short of the market’s revenue expectations in Q3 2026, with revenue falling 3% year on year to $2.20 billion. The company’s full-year revenue guidance of $8.95 billion at the midpoint came in 2.6% below analysts’ consensus estimates. Its non-GAAP profit of $1.44 per share was 0.7% below analysts’ consensus estimates.

For more on Xylem, read the full research report for free.

“We’re moving with urgency to shape Xylem around the markets where our capabilities can deliver the greatest customer value and strongest long-term growth," said Matthew Pine, president and CEO of Xylem. "The resilience we’ve built, evident this quarter, allows us to make those choices deliberately and from a position of strength.”

Revenue growth

A company’s long-term revenue performance can indicate its overall quality. Even a poor business can perform well for one or two quarters, but a high-quality one grows for years. Xylem’s revenue grew at an impressive 11.5% compounded annual growth rate over the last five years. Its growth beat the average industrials company and shows its offerings resonate with customers.

Long-term growth is the most important, but within industrials, a half-decade historical view may miss new industry trends or demand cycles. Xylem’s recent performance shows its demand has slowed significantly as its annualized revenue growth of 3.7% over the last two years was well below its five-year trend.

Xylem also reports organic revenue, which strips out one-time events like acquisitions and currency fluctuations that don’t accurately reflect its fundamentals. Over the last two years, Xylem’s organic revenue averaged 4.3% year-on-year growth. This was in line with its two-year revenue growth, indicating that core operations, rather than acquisitions and divestitures, drove most of its results.

This quarter, Xylem missed Wall Street’s consensus estimates and reported an uninspiring 3% year-on-year revenue decline, generating $2.20 billion of revenue.

Looking ahead, sell-side analysts expect revenue to grow 4.7% over the next 12 months, according to S&P, similar to its two-year rate. This uninspiring projection implies its newer products and services will not accelerate its revenue growth yet. On the positive side, the company is tracking well in other measures of financial health.

Operating margin

Operating margin is one of the best measures of profitability because it shows how much money a company takes home after procuring and manufacturing its products, marketing and selling those products and most importantly, keeping them relevant through research and development.

Xylem has been an efficient company over the last five years. It was one of the more profitable businesses in the industrials sector, with an average operating margin of 12.1%. This result isn’t surprising as its high gross margin gives it a favorable starting point.

Looking at the trend in its profitability, Xylem’s operating margin rose by 4.6 percentage points over the last five years, as its revenue growth gave it operating leverage.

This quarter, Xylem generated an operating margin of 17.5%, up 2.8 percentage points year on year. The increase was a positive sign. Operating margin rose more than gross margin, suggesting it was more efficient with expenses such as marketing, R&D and administrative overhead.

Earnings per share

Revenue trends explain a company’s historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth. For example, a company could inflate its revenue through excessive spending on advertising and promotions.

Xylem’s EPS grew at a 15.4% compounded annual growth rate over the last five years, higher than its 11.5% annualized revenue growth. This tells us the company became more profitable on a per-share basis as it expanded.

A closer look at Xylem’s earnings quality helps explain its performance. As noted earlier, Xylem’s operating margin expanded by 4.6 percentage points over the last five years. This was the most relevant factor (aside from the revenue impact) behind its higher earnings; interest expenses and taxes can also affect EPS but don’t tell us as much about a company’s fundamentals.

As with revenue, examining EPS over a shorter period can help identify changes in the business.

For Xylem, its two-year annual EPS growth of 15.3% is similar to its five-year trend, implying strong and stable earnings power.

In Q3, Xylem reported adjusted EPS of $1.44, up from $1.37 in the same quarter last year. This result was close to analysts’ consensus estimates. Over the next 12 months, Wall Street expects Xylem’s full-year EPS to grow 10.1% from $5.44 to $5.99, according to S&P.

Key takeaways from Xylem’s Q3 results

Xylem’s revenue fell short of Wall Street’s consensus estimates, and its full-year EPS guidance also missed expectations, leaving few positives in a weaker quarter. Shares tumbled 5.9% to $101.97 immediately after the release.

Xylem had an underwhelming quarter, but does that create an opportunity to buy the stock at its current price? If you’re making that decision, consider the bigger picture of valuation, business quality and the latest earnings. For more on Xylem, read our full research report here (it’s free).